Restoring Health & Mobility

Aziyo Biologics, Inc. was created by HighCape Partners with the mission of restoring health and mobility to the greatest number of patients. Our vision is to impact healthcare through innovation of new solutions realizing the commercial potential of regenerative medicine. Aziyo is built on long-standing corporate partners and deep product development and biologics processing expertise.

AZO003-Interior-Large-Squares-2At Aziyo, we have witnessed first-hand that a transplanted ligament can enable mobility, a bone spinal implant can ease chronic pain, and a skin graft can bring much-needed relief to a burn victim.

These life-changing solutions fuel our utmost respect for the gift of donation and drive our dedication to scientific and operational excellence.

LEARN MORE ABOUT THE GIFT OF DONATION

Leadership

Leadership
Team

Kevin Rakin

Kevin Rakin
Interim President and Chief Executive Officer
Read Bio

Michelle LeRoux Williams, Ph.D.

Michelle LeRoux Williams, Ph.D.
Chief Scientific Officer
Read Bio

Andrew M. Green

Andrew M. Green
Chief Business Officer
Read Bio

Darryl Roberts, Ph.D.

Darryl Roberts, Ph.D.
Sr. VP, Operations and General Manager, Richmond
Read Bio

Jeff Hamet

Jeff Hamet
VP, Finance
Read Bio

Patrick Ferguson

Patrick Ferguson
Vice President of Cardiovascular Sales
Read Bio

Kevin Armstrong

Kevin Armstrong
Vice President of Orthopedic Sales
Read Bio

Dana Yoo, Ph.D.

Dana Yoo, Ph.D.
VP, Research & Development
Read Bio

Erica Elchin

Erica Elchin
VP, Technical Services
Read Bio


Board of
Directors

Kevin Rakin
Executive Chairman
Read Bio

C. Randal Mills, Ph.D.
Board Member
Read Bio

Matt Zuga
Board Member
Read Bio

Steven Hochberg
Board Member
Read Bio

Newsroom

Press
Releases

11.15.17 Aziyo Presents Positive Initial Data from Clinical Study of Biologic Extracellular Matrix Scaffold for Femoral Arterial Reconstruction

SILVER SPRING, MD. – Aziyo Biologics, Inc., a fully integrated regenerative medicine company, today announced positive results from PERFORM, a prospective, post-market study conducted in patients undergoing femoral arterial reconstruction using the company’s biologic extracellular matrix (ECM) scaffold.  There were no device-related adverse events or infections and primary patency was maintained in 97.6% of procedures. The…

Read More
11.03.17 Aziyo Launches CanGaroo Bio Envelope for Subcutaneous Implantable Cardioverter-Defibrillators

SILVER SPRING, MD. – Aziyo Biologics, Inc., a fully integrated regenerative medicine company, today announced the launch of a new CanGaroo Bio Envelope specifically for use with subcutaneous implantable cardioverter-defibrillators (S-ICDs). This is the only cardiac implantable electronic device (CIED) envelope available for use with S-ICDs. CanGaroo is a natural extracellular matrix (ECM) scaffold that is…

Read More
08.29.17 Aziyo Completes Enrollment in Prospective Post Market Study of CanGaroo ECM Envelope

SILVER SPRING, MD. – Aziyo Biologics, Inc. a fully integrated regenerative medicine company, today announced completion of patient enrollment in SECURE, a prospective post market study of 1,000 patients treated with CanGaroo® ECM® Envelope in conjunction with cardiac implantable electronic device (CIED) placement. The CanGaroo ECM Envelope is intended to securely hold a CIED to…

Read More
05.31.17 Aziyo Continues Building New Breed of Regenerative Medicine Company

Commercial portfolio expanded with acquisition of CorMatrix® products

Read More
11.05.15 HighCape Partners and Tissue Banks International Partner to Create Cutting Edge Regenerative Medicine Company Aziyo Biologics

HighCape Partners and Tissue Banks International Partner to Create Cutting Edge Regenerative Medicine Company Aziyo Biologics

Read More

Investors

Aziyo Biologics is supported by HighCape Partners, a growth equity fund focused on investing in commercial-stage life sciences companies, Deerfield Management, an investment management firm, Midcap Financial, a specialty finance firm, and Keralink, a leading network of ocular centers.